Abstracts Banner

Important Dates

October 2018

November 30, 2018, 11:59 pm PST

November 30, 2018, 11:59 pm PST

December 20, 2018
Online abstract submission site opens

Deadline to submit an abstract

Deadline to submit for an award

Acceptance/rejection communicated
January 4, 2019

February 19, 2019

March 25, 2019

April 2 - 6, 2019
Early Bird rate ends

Deadline for Poster withdrawal

Platform PowerPoint presentation deadline

ACMG Annual Clinical Genetics Meeting
To submit an abstract, the following criteria must be met:
Research and/or studies must fit into one of the ACMG 2019 Abstract Review Categories.
  - Clinical Genetics
  - Cancer Genetics
  - Molecular Genomics/Exome Sequencing
  - Clinical Cytogenetics and Genomics
  - Pre-and Perinatal Genetics
  - Biochemical/Metabolic Genetics
  - Genetic Counseling
  - Health Services/Implementation
  - Legal and Ethical Issues
  - Education
  - Therapeutics
• The first author listed for each abstract serves as the presenting author and as the primary contact for all correspondence regarding the abstract, unless otherwise specified under the “Contact Information” section of the online abstract submission system.
• The presenting author is the First Author and must be one of the co-authors listed on the submitted abstract.
• The presenting author is responsible for the following:
    - Ensuring that all authors have read the abstract and agreed to be co-authors. Failure to get approval from all authors will result in rejection of the abstract.
    - Notifying all co-authors of any additions, deletions, and changes to the program, as may be communicated by ACMG.
    - Obtaining all of the conflict-of-interest disclosure and copyright transfer information from co-authors. This information is to be kept on file by the presenting author. If the abstract is accepted for a platform presentation, then the documentation may be requested by the ACMG office for review.
    - If accepted for a platform presentation then the presenting author must forward all correspondence to all co-authors, including ACMG policies and guidelines and the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support for Continuing Medical Education (CME). These documents can be downloaded upon platform acceptance.
• An individual may be first author (i.e., presenting author) of more than one abstract. If the first author should have multiple accepted posters and has a conflict with the poster presentation schedule, then it is acceptable to designate one of the co- authors to present one of the posters. The abstract number determines the schedule. The number of an abstract cannot be changed.
Each abstract author agrees and certifies that he or she:
- has read all of the rules and agrees to be bound by them,
- is responsible for submission of the abstract in accordance with the rules, and
- waives any and all claims against ACMG and any reviewer arising out of or relating to the abstract submission and review process, including but not limited to peer review and the grading of abstracts.
• The abstract must address scientific questions, detail clinical observations, or contain primary scientific data.
• Authors assign copyright of the abstract to ACMG upon submission, unless one of the authors is a U.S. Federal employee (in such case, ACMG does not hold copyright). This means that the identical abstract may not be republished or submitted to another meeting.
• All research and studies reported in submitted abstracts that involve human and animal subjects must comply with the guiding principles for experimental procedures found in the Declaration of Helsinki of the World Medical Association.
• Interim analysis of a prospective randomized clinical trial will be considered only if it is performed as planned in the original protocol and is statistically valid. If your abstract involves interim analysis, use the Interim Analysis of a Clinical Trial section of the abstract form to explain the details of your study. The reviewers will have this information available during their evaluation.
• No revisions can be made after the abstract submission deadline (November 30, 2018).
• The presentation at the annual meeting must reflect the submitted abstract. In particular, the abstract title, authorship, and scientific content of the presentation at the annual meeting must match the submitted abstract, although updates on results may be added by November 30, 2018.
• Abstracts should be written in clear and concise English, so that reviewers can focus solely on the scientific merits of the submission. We encourage non-English-speaking authors to have their abstracts checked for grammar and spelling prior to submission.
• It is assumed that the presenting author will have adequate command of English to present and to respond to questions. If that is not the case, the authors should choose a poster as their preference.
• Abstracts can be submitted if:
- It is unpublished and original
- Accepted for publication but not yet published
- Encore presentations are allowed, only if material was previously presented at a non-genetics meeting within the last 6 – 12 months.
During submission, submitters must choose the formats in which they would like to present their abstract. The choice must be made at the time of submission and cannot be changed after the review committee has reached its decision.
Submission format options:

1. Poster Presentation Only
2. Platform Presentation Only
3. Platform or Poster Presentation (abstract is reviewed and if accepted, it will be either as a platform or a poster presentation)

Authors select presentation format for submission (above). Abstracts noted with a preference for poster presentation only will NOT be considered for a platform presentation, regardless of score.